Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

References

• Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, et al. Harnessing graft-versus-malignancy: nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation. An evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 11: 18–29
   Web of Science ®Google Scholar
• Shimoni A, Nagler A. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Curr Hematol Rep 2004; 3: 242–248
   PubMedGoogle Scholar
• Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998; 91: 756–763
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328
   PubMed Web of Science ®Google Scholar
• Hartley J A, O'Hare C C, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79: 264–266
   PubMed Web of Science ®Google Scholar
• Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998; 71: 94–98
   PubMed Web of Science ®Google Scholar
• Schmidmaier R, Oellerich M, Baumgart J, Emmerich B, Meinhardt G. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol 2004; 32: 76–86
   PubMed Web of Science ®Google Scholar
• Fichtner I, Becker M, Baumgart J. Antileukaemic activety of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003; 39: 801–807
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004; 34: 477–483
   PubMed Web of Science ®Google Scholar
• Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B, Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003; 122: 892–899
   PubMed Web of Science ®Google Scholar
• Ploemacher R E, Johnson K W, Rombouts E J, Etienne K, Westerhof G R, Baumgart J, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236–245
   PubMed Web of Science ®Google Scholar
• Westerhof G R, Ploemacher R E, Boudewijn A, Blokland I, Dillingh J H, McGown T, et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470–5478
   PubMed Web of Science ®Google Scholar
• Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 2006; 34: 115–121
   PubMed Web of Science ®Google Scholar
• Scheulen M E, Hilger R A, Oberhoff C, Casper J, Freund M, Josten K M, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216
   PubMed Web of Science ®Google Scholar
• Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731
   PubMed Web of Science ®Google Scholar
• Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol 2004; 83(Suppl 1)S70–S71
   PubMedGoogle Scholar
• Beelen D W, Trenschel R, Casper J, Freund M, Hilger R A, Scheulen M E, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233–241
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006; 37: 339–344
   PubMed Web of Science ®Google Scholar
• Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967–1975
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457–481
   Web of Science ®Google Scholar
• Gooley T A, Leisenring W, Crowley J, Storer B E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706
   PubMed Web of Science ®Google Scholar
• Alyea E P, Kim H T, Ho V, Cutler C, Gribben J, DeAngelo D J, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814
   PubMed Web of Science ®Google Scholar
• Aoudjhane M, Labopin M, Gorin N C, Shimoni A, Ruutu T, Kolb H J, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312
   PubMed Web of Science ®Google Scholar
• van Pel M, van Breugel D W, Vos W, Ploemacher R E, Boog C J. Towards a myeloablative regimen with clinical potential. I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 2003; 32: 15–22
   PubMed Web of Science ®Google Scholar
• van Pel M, van Breugel D W, Vos W, Ploemacher R E, Boog C J. Toward a myeloablative regimen with clinical potential. II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant 2004; 33: 153–159
   PubMed Web of Science ®Google Scholar
• Antin J H, Ferrara J L. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–2968
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi M, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens prior to allogeneic stem cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 2007; 21: 2109–2116
   PubMed Web of Science ®Google Scholar